Recombinant Mouse antibody to Human NGcGM3. Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
Figure 1 Antitumor protection against spontaneous lung nodule formation by immunization with racotumomab-alum.
Mice were inoculated subcutaneously with 3LL cells and immunized with racotumomab-alum at a dose of 50 μg, as described in "Materials and Methods." Subcutaneous primary tumor growth.
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Figure 2 Effects of racotumomab-alum immunization and chemotherapy on spontaneous lung nodule formation.
Mice were inoculated subcutaneously with 3LL cells, and then immunized with racotumomab-alum (raco-alum) at 50 μg/dose and/or administered with pemetrexed (100 mg/kg).
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Figure 3 NeuGc-specific humoral response elicited by racotumomab-alum vaccination.
Mice were challenged subcutaneously with 3LL cells preincubated or not with purified NeuGc, and immunized with racotumomab-alum (raco-alum) at 50 μg/dose. Flow cytometric analysis.
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Figure 4 Racotumomab-alum induces NeuGc-specific humoral response.
Mice were challenged subcutaneously with 3LL cells preincubated or not with purified NeuGc, and immunized with racotumomab-alum (raco-alum) at 50 μg/dose. Percent of recognized X63 cells.
Segatori, V. I., Vazquez, A. M., Gomez, D. E., Gabri, M. R., & Alonso, D. F. (2012). Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Frontiers in oncology, 2, 160.
Figure 5 Immune response induced in racotumomab/alum-vaccinated patients.
Survival of patients with cytotoxic antibodies killing 30% or more (red line) L1210 cells versus patients with less than 30% lysis (blue line).
Hernández, A. M., & Vázquez, A. M. (2015). Racotumomab–alum vaccine for the treatment of non-small-cell lung cancer. Expert review of vaccines, 14(1), 9-20.
Figure 6 Maximal titers of anti-racotumomab and anti-NeuGc-GM3 antibody responses for all evaluable patients in each dose level.
Specificity controls are shown as empty circles (mouse IgG1 isotype control) and empty lozenges (NeuAc-GM3 ganglioside).
Cacciavillano, W., Sampor, C., Venier, C., Gabri, M. R., de Dávila, M. T., Galluzzo, M. L., ... & Chantada, G. L. (2015). A Phase I Study of the Anti‐Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. Pediatric blood & cancer, 62(12), 2120-2124.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-NGCGM3 ADCC Recombinant Antibody (Racotumomab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Mouse antibody to Human NGcGM3. Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-663 | Human Anti-NGCGM3 Recombinant Antibody (clone chP3) | ELISA | Chimeric (mouse/human) IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
PFBL-657 | Human Anti-NGCGM3 Recombinant Antibody (clone chP3); Fab Fragment | ELISA | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-657 | Mouse Anti-NGCGM3 Recombinant Antibody (clone chP3); scFv Fragment | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-H58 | Afuco™ Anti-NGCGM3 ADCC Recombinant Antibody (Racotumomab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-H58. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.